CRESCENT BIOPHARMA, INC. (CBIO) has 15 SEC Form 4 insider filings on record in the last 90 days. That includes 1 insider purchase totalling $20.0M, and 14 sales totalling $1.5M. Most recent filing: Sept. 18, 2026.
| Date | Insider | Value | Shares | Stake | Pre-planned | Links |
|---|---|---|---|---|---|---|
| Sept. 18, 2026 filed Sept. 16, 2026 | Lynch Ryan See Remarks | −$4,296 | 240 | −2% | Yes | |
|
|
||||||
| Sept. 18, 2026 filed Sept. 16, 2026 | Pinkas Jan Chief Scientific Officer | −$11,778 | 658 | −3% | Yes | |
|
|
||||||
| Sept. 18, 2026 filed Sept. 16, 2026 | Im Ellie Eunkyung Chief Medical Officer | −$11,152 | 623 | −3% | Yes | |
|
|
||||||
| Sept. 18, 2026 filed Sept. 16, 2026 | Scalzo Richard William Chief Financial Officer | −$10,167 | 568 | −3% | Yes | |
|
|
||||||
| Sept. 18, 2026 filed Sept. 16, 2026 | McNeill Jonathan President and COO | −$77,235 | 4,570 | −3% | Yes | |
|
|
||||||
Showing the 5 most recent of 15 filings in the last 90 days.
Form 4 is the filing company officers, directors and 10% shareholders must submit to the SEC within two business days of trading their own company's stock. Open-market purchases generally carry more signal than sales, which are often scheduled in advance. More on how this works.
Real-time Telegram alerts the moment a Form 4 is filed. Filings shown here are delayed by 72 hours.
Start free